A recent “Buy” rating from Citigroup on Fortis Healthcare Limited has positioned this significant player in India’s healthcare sector for considerable attention from investors and industry observers alike. The prominent brokerage firm has set a target price of Rs. 1,120 per share, suggesting an impressive upside potential of 44 percent from its current trading price of Rs. 780 per equity share. This endorsement underscores a compelling narrative of anticipated growth, operational efficiencies, and strategic backing, even as the company navigates temporary external headwinds affecting its international patient segments. As a mid-cap healthcare stock with a market capitalization of Rs. 59,000 crore, Fortis Healthcare Limited continues to be a pivotal entity in India’s evolving medical tourism landscape, delivering comprehensive hospital, diagnostic, and healthcare services across its extensive network.
Citigroup’s Bullish Outlook on Fortis Healthcare
Citigroup’s reiterated